Browsing Tag
Acellular Tissue Engineered Vessel
2 posts
Humacyte (HUMA) posts positive Phase 3 dialysis access data, then raises $50m at a discount on the strength of it
Humacyte (HUMA) posts positive Phase 3 dialysis access data and raises $50M at a discount. FDA filing planned for H2 2026. Read the full executive analysis.
Is ATEV the first scalable alternative to autologous fistulas in hemodialysis access
Can Humacyte, Inc. turn ATEV into a viable dialysis access alternative? Dive into Phase 3 signals, risks, and market impact shaping its future.